

# Aleglitazar

## Catalog No: tcsc1134



### Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



### Specifications

**CAS No:**

475479-34-6

**Formula:**

$C_{24}H_{23}NO_5S$

**Pathway:**

Cell Cycle/DNA Damage

**Target:**

PPAR

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

R1439;RO0728804

**Observed Molecular Weight:**

437.51


## Product Description

Aleglitazar(R1439; RO-0728804) is a new dual PPAR- $\alpha/\gamma$  agonist with IC<sub>50</sub> of 2.8 nM/4.6 nM.

IC<sub>50</sub> Value: 2.8 nM(PPAR- $\alpha$ ); 4.6 nM(PPAR- $\gamma$ )

Target: PPAR $\alpha/\gamma$

Aleglitazar (R1439) is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with affinity to PPAR $\alpha$  and PPAR $\gamma$ . Aleglitazar is being developed for the treatment of type II diabetes; It is currently in phase III clinical trials. In preliminary clinical studies, Aleglitazar has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. Aleglitazar has beneficial effects on both lipid and glucose parameters and may have a therapeutic role in modifying cardiovascular risk factors and improving glycemic control in patients with T2DM. Aleglitazar combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!